Study | Number of patients (LS and ES) | Median overall survival (months) | ||
---|---|---|---|---|
All patients | Limited stage | Extensive stage | ||
Brennan et al13 | 120 (84 and 36) | – | 16.8 | 8.4 |
Cicin et al20 | 11 (3 and 8) | 10 | 17 | 5 |
Current study | 159 (87 and 70) | 13.4 | 19.5 | 7.6 |
Dakhil et al26 | 35 (20 and 15) | – | 36 | 5 |
Haider et al14 | 101 (51 and 50) | 9.38 | 34 | 2 |
Kim et al18 | 34 (23 and 11) | 14 | 19.8 | 7 |
Naidoo et al23 | 288 (65 and 186)* | – | 15.2 | 2.3 |
Terashima et al21 | 41 (0 and 41)† | 9.2 | 0 | 9.2 |
Wong et al12 | 1618 (532 and 682)‡ | – | 12 | 3.4 |
*In 29 patients (10.3%) stage was unknown.
†‘Extrapulmonary neuroendocrine carcinomas’.
‡In 604 patients (37.3%) the stage was unknown.